Sponsored Research and Clinical Trial Agreements - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|---|---|
Jun. 30, 2020 |
May 31, 2020 |
Jun. 30, 2020 |
Jun. 30, 2019 |
Jun. 30, 2020 |
Jun. 30, 2019 |
Dec. 31, 2019 |
|
Research and Development Expense (Excluding Acquired in Process Cost) | $ 15,703 | $ 18,511 | $ 30,570 | $ 41,784 | |||
Aevitas [Member] | |||||||
Cost of the SRA | 0 | 0 | 300 | 500 | |||
Cellvation [Member] | |||||||
Research and Development Expense (Excluding Acquired in Process Cost) | 0 | $ 0 | 100 | $ 100 | |||
Mustang Bio, Inc [Member] | |||||||
Maximum cost associated with COH | $ 2,400 | ||||||
Payments for research and development expenses | 800 | ||||||
Oncogenuity [Member] | |||||||
Cost of the SRA | 100 | $ 0 | |||||
Funding commitment period | 5 years | ||||||
Payments for research and development expenses | $ 400 | $ 400 | |||||
Oncogenuity [Member] | Maximum [Member] | |||||||
Sponsor research agreement funding commitment | $ 4,800 |
X | ||||||||||
- Definition The amount represents maximum cost associated with COH. No definition available.
|
X | ||||||||||
- Definition The amount of cash outflow associated research and development expenses paid during the period. No definition available.
|
X | ||||||||||
- Definition The amount of funding commitment for a sponsor research agreement. No definition available.
|
X | ||||||||||
- Definition Period over which the funding is committed to be made under the Sponsor Research Agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
X | ||||||||||
- Definition Represents the cost of the sponsored research arrangement. No definition available.
|
X | ||||||||||
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|